Gene Editing Technologies: CRISPR and Beyond

Gene therapy is emerging as a transformative approach for treating a variety of ophthalmic diseases, offering the potential to correct genetic defects, halt disease progression, and restore vision. Ophthalmic diseases, such as inherited retinal dystrophies, age-related macular degeneration (AMD), and glaucoma, can significantly impact quality of life, and gene therapy provides a promising avenue for long-term treatment and possible cures. Employing RNA interference (RNAi) or antisense oligonucleotides to silence the expression of harmful genes. This is useful for conditions caused by gain-of-function mutations or toxic protein production. Gene therapy research for RP involves various approaches, including gene augmentation, gene editing, and optogenetics, targeting different genetic mutations associated with the disease. Gene therapy for glaucoma focuses on neuroprotection and lowering intraocular pressure. This includes delivering genes that protect retinal ganglion cells from degeneration or enhance the outflow of aqueous humor to reduce pressure.

    Related Conference of Gene Editing Technologies: CRISPR and Beyond

    May 19-20, 2025

    8th Global Conference on Cell and Gene Therapy

    Singapore City, Singapore
    June 16-17, 2025

    21st Global Summit on Stem Cell & Regenerative Medicine

    Frankfurt, Germany
    July 21-22, 2025

    18th World Congress on Stem Cell Research

    Barcelona, Spain

    Gene Editing Technologies: CRISPR and Beyond Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in